Related Experiment Video
Updated: Jul 7, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chemoresistance in gliomas
1Brain Tumour North West, Faculty of Science, University of Central Lancashire, Preston, UK.
Molecular and Cellular Biochemistry
|February 9, 2008
Summary
Glioma treatment faces challenges due to multidrug resistance (MDR) and cancer stem cells (CSCs). Targeting these factors offers new therapeutic strategies for improving glioma patient survival rates.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Gliomas have a poor survival rate despite advances in treatment.
- Tumor heterogeneity, including multidrug resistant (MDR) phenotypes and cancer stem cells (CSCs), contributes to treatment resistance in gliomas.
Purpose of the Study:
- To review the molecular mechanisms and genes associated with MDR in gliomas.
- To discuss the role of MDR phenotypes in glioma CSCs.
- To explore potential future therapies targeting MDR and CSCs.
Main Methods:
- Literature review of MDR-related genes (e.g., MVP, Bcl-2).
- Analysis of molecular mechanisms contributing to chemoresistance.
- Examination of upregulated MDR phenotypes in glioma CSCs.
Main Results:
- MDR phenotypes and CSCs are key contributors to glioma treatment failure.
- Specific genes like MVP and Bcl-2 are implicated in MDR.
- Upregulated MDR phenotypes are identified within glioma CSCs.
Conclusions:
- Understanding MDR mechanisms is crucial for developing effective glioma treatments.
- Combined therapies targeting both CSCs and their MDR phenotypes show promise.
- Novel strategies are needed to overcome chemoresistance and improve patient outcomes.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...